The Korean journal of internal medicine

  • 제31권3호
  • /
  • Pages.488-500
  • /
  • 2016
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Immediate multivessel revascularization may increase cardiac death and myocardial infarction in patients with ST-elevation myocardial infarction and multivessel coronary artery disease: data analysis from real world practice

  • Chung, Woo-Young (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Seo, Jae-Bin (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Choi, Dong-Hyun (Department of Internal Medicine, Chosun University Hospital) ;
  • Cho, Young-Seok (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Lee, Joo Myung (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center) ;
  • Suh, Jung-Won (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Youn, Tae-Jin (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Chae, In-Ho (Department of Internal Medicine, Seoul National University College of Medicine) ;
  • Choi, Dong-Ju (Department of Internal Medicine, Seoul National University College of Medicine)
  • 투고 : 2014.04.29
  • 심사 : 2015.03.11
  • 발행 : 2016.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: The best revascularization strategy for patients with both acute ST-elevation myocardial infarction (STEMI) and multivessel coronary disease (MVD) is still debatable. We aimed to compare the outcomes of multivessel revascularization (MVR) with those of culprit-only revascularization (COR). Methods: A cohort of 215 consecutive patients who had received primary angioplasty for STEMI and MVD were divided into two groups according to whether angioplasty had been also performed for a stenotic nonculprit artery. The primary endpoint was one-year major adverse cardiac events defined as a composite of cardiac death, recurrent myocardial infarction, or any repeat revascularization. Results: One-year major adverse cardiac events were not significantly different between MVR (n = 107) and COR (n = 108) groups. However, the one-year composite hard endpoint of cardiac death or recurrent myocardial infarction was notably increased in the MVR group compared to the COR group (20.0% vs. 8.9%, p = 0.024). In subgroup analysis, the hard endpoint was significantly more frequent in the immediate than in the staged MVR subgroup (26.6% vs. 9.8%, p = 0.036). The propensity score-matched cohorts confirmed these findings. Conclusions: In patients with STEMI and MVD, MVR, especially immediate MVR with primary percutaneous intervention, was not beneficial and led to worse outcomes. Therefore, we conclude that COR or staged MVR would be better strategies for patients with STEMI and MVD.

키워드

참고문헌

  1. Keeley EC, Grines CL. Primary coronary intervention for acute myocardial infarction. JAMA 2004;291:736-739. https://doi.org/10.1001/jama.291.6.736
  2. Muller DW, Topol EJ, Ellis SG, Sigmon KN, Lee K, Califf RM. Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1991;121(4 Pt 1):1042-1049. https://doi.org/10.1016/0002-8703(91)90661-Z
  3. Jaski BE, Cohen JD, Trausch J, et al. Outcome of urgent percutaneous transluminal coronary angioplasty in acute myocardial infarction: comparison of single-vessel versus multivessel coronary artery disease. Am Heart J 1992;124:1427-1433. https://doi.org/10.1016/0002-8703(92)90053-X
  4. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619. https://doi.org/10.1093/eurheartj/ehs215
  5. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362-e425. https://doi.org/10.1161/CIR.0b013e3182742cf6
  6. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation 2009;119:1330-1352. https://doi.org/10.1161/CIRCULATIONAHA.108.191768
  7. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010;31:943-957. https://doi.org/10.1093/eurheartj/ehp492
  8. Di Mario C, Mara S, Flavio A, et al. Single vs multivessel treatment during primary angioplasty: results of the multicentre randomised HEpacoat for cuLPrit or multivessel stenting for Acute Myocardial Infarction (HELP AMI) Study. Int J Cardiovasc Intervent 2004;6:128-133. https://doi.org/10.1080/14628840310030441
  9. Khattab AA, Abdel-Wahab M, Rother C, et al. Multi-vessel stenting during primary percutaneous coronary intervention for acute myocardial infarction: a single-center experience. Clin Res Cardiol 2008;97:32-38. https://doi.org/10.1007/s00392-007-0570-4
  10. Qarawani D, Nahir M, Abboud M, Hazanov Y, Hasin Y. Culprit only versus complete coronary revascularization during primary PCI. Int J Cardiol 2008;123:288-292. https://doi.org/10.1016/j.ijcard.2006.12.013
  11. Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010;96:662-667. https://doi.org/10.1136/hrt.2009.177162
  12. Corpus RA, House JA, Marso SP, et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J 2004;148:493-500. https://doi.org/10.1016/j.ahj.2004.03.051
  13. Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;369:1115-1123. https://doi.org/10.1056/NEJMoa1305520
  14. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e1-e157. https://doi.org/10.1016/j.jacc.2007.11.004
  15. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000;102:2031-2037. https://doi.org/10.1161/01.CIR.102.17.2031
  16. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat 2011;10:150-161. https://doi.org/10.1002/pst.433
  17. Grines CL, Topol EJ, Califf RM, et al. Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction: the TAMI Study Groups. Circulation 1989;80:245-253. https://doi.org/10.1161/01.CIR.80.2.245
  18. Gibson CM, Ryan KA, Murphy SA, et al. Impaired coronary blood flow in nonculprit arteries in the setting of acute myocardial infarction: the TIMI Study Group. Thrombolysis in myocardial infarction. J Am Coll Cardiol 1999;34:974-982. https://doi.org/10.1016/S0735-1097(99)00335-6
  19. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000;343:915-922. https://doi.org/10.1056/NEJM200009283431303
  20. Nath A, DiSciascio G, Kelly KM, et al. Multivessel coronary angioplasty early after acute myocardial infarction. J Am Coll Cardiol 1990;16:545-550. https://doi.org/10.1016/0735-1097(90)90340-U
  21. Chen LY, Lennon RJ, Grantham JA, et al. In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. Am J Cardiol 2005;95:349-354. https://doi.org/10.1016/j.amjcard.2004.09.032
  22. Cavender MA, Milford-Beland S, Roe MT, Peterson ED, Weintraub WS, Rao SV. Prevalence, predictors, and in-hospital outcomes of non-infarct artery intervention during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (from the National Cardiovascular Data Registry). Am J Cardiol 2009;104:507-513. https://doi.org/10.1016/j.amjcard.2009.04.016
  23. Toma M, Buller CE, Westerhout CM, et al. Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. Eur Heart J 2010;31:1701-1707. https://doi.org/10.1093/eurheartj/ehq129
  24. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol 2010;56:177-184. https://doi.org/10.1016/j.jacc.2010.04.012
  25. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-224. https://doi.org/10.1056/NEJMoa0807611
  26. Ntalianis A, Sels JW, Davidavicius G, et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv 2010;3:1274-1281. https://doi.org/10.1016/j.jcin.2010.08.025
  27. Tonino PA, Fearon WF, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 2010;55:2816-2821. https://doi.org/10.1016/j.jacc.2009.11.096
  28. Legalery P, Schiele F, Seronde MF, et al. One-year outcome of patients submitted to routine fractional flow reserve assessment to determine the need for angioplasty. Eur Heart J 2005;26:2623-2629. https://doi.org/10.1093/eurheartj/ehi484
  29. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281. https://doi.org/10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
  30. Brener SJ, Lincoff AM, Bates ER, et al. The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial. Am Heart J 2005;150:89-93. https://doi.org/10.1016/j.ahj.2005.01.030
  31. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001;286:1356-1359. https://doi.org/10.1001/jama.286.11.1356
  32. Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 2005;112:2017-2021. https://doi.org/10.1161/CIRCULATIONAHA.105.558676
  33. Jo HS, Park JS, Sohn JW, et al. Culprit-lesion-only versus multivessel revascularization using drug-eluting stents in patients with ST-segment elevation myocardial infarction: a Korean acute myocardial infarction registry-based analysis. Korean Circ J 2011;41:718-725. https://doi.org/10.4070/kcj.2011.41.12.718

피인용 문헌

  1. Culprit Vessel-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment-Elevation Myocardial Infarction : A Collaborative Meta-Analysis vol.10, pp.11, 2016, https://doi.org/10.1161/circinterventions.117.005582